Search results for: 'deal congest strategi 2016'

Option and Evaluation Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026

Global coverage | Deal financials | Contract documents | Deal trends | Leading M&A dealmakers | Comprehensive deal directory 2021 to 2026

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025

Drug Delivery Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Regenerative Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Central Nervous System (CNS) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2020 to 2025

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2026 | 11+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals